CalciMedica Inc (nasdaq:CALC) Share Price

Company Profile

Business description
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
Contact
505 Coast Boulevard South
Suite 307
La JollaCA92037
USA
T: +1 858 952-5500
E: [email protected]
https://www.calcimedica.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
16

Recommended

Headwinds in listed energy stocks likely to have passed

Esther Holloway | 30 March 2026

Potential investors should remember that the company’s controlling shareholder can move markets with a few words.

Franco Granda | 30 March 2026

What we can and can’t learn from the top 20 most shorted ASX shares.

Tyger Fitzpatrick | 30 March 2026

Index	Last price	Change	% Change
All Ordinaries	8,747.40	75.00	0.86%
CAC 40	7,772.45	70.50	0.92%
DAX 40	22,562.88	262.13	1.18%
Dow JONES (US)	45,216.14	49.50	0.11%
FTSE 100	10,127.96	160.61	1.61%
HKSE	24,657.41	93.38	-0.38%
NASDAQ	20,794.64	153.72	-0.73%
Nikkei 225	51,820.30	65.55	-0.13%
NZX 50 Index	12,866.42	117.50	0.92%
S&P 500	6,343.72	25.13	-0.39%
S&P/ASX 200	8,546.50	69.30	0.82%
SSE Composite Index	3,910.01	13.27	-0.34%